ProMIS Neurosciences, Inc. (PMN) - Long-Term Debt to Capital

Despite management's authority in treating neurodegeneration, the long-term debt-to-equity ratio on the GURU.Markets terminal analytical chart is recorded at 0.00, which may mask stagnation. However, flexible outsourcing of production and trials minimizes costs, while robust R&D investments in developing selective antibodies against Alzheimer's disease confirm the high potential of ProMIS Neurosciences (PMN).

Managers evaluate the operating model of ProMIS Neurosciences (PMN) through the lens of financial stability. This metric compares liabilities with a maturity of over one year against equity to measure the degree of reliance on borrowed funds. Analyzing long-term credit leverage allows for an assessment of bankruptcy risk in the event of a high burn rate. Given the costly nature of Alzheimer's disease research, an increase in this metric signals a critical dependence on external financing, which calls into question the long-term autonomy of ProMIS Neurosciences (PMN).